GSA Capital Partners LLP Grows Position in Outset Medical, Inc. (NASDAQ:OM)

GSA Capital Partners LLP grew its position in Outset Medical, Inc. (NASDAQ:OM) by 924.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,111,612 shares of the company’s stock after purchasing an additional 1,003,135 shares during the quarter. GSA Capital Partners LLP owned approximately 2.13% of Outset Medical worth $753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of OM. Massachusetts Financial Services Co. MA lifted its position in shares of Outset Medical by 118.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after acquiring an additional 834,663 shares in the last quarter. Millennium Management LLC lifted its holdings in Outset Medical by 58.8% in the 2nd quarter. Millennium Management LLC now owns 1,942,899 shares of the company’s stock worth $7,480,000 after purchasing an additional 719,412 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Outset Medical by 369.4% in the 1st quarter. Acadian Asset Management LLC now owns 779,242 shares of the company’s stock worth $1,728,000 after purchasing an additional 613,229 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Outset Medical by 60.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,515,126 shares of the company’s stock worth $5,833,000 after purchasing an additional 570,281 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in Outset Medical by 103.7% during the 1st quarter. Lazard Asset Management LLC now owns 523,860 shares of the company’s stock valued at $1,162,000 after buying an additional 266,717 shares in the last quarter.

Outset Medical Trading Down 8.0 %

OM stock opened at $0.79 on Monday. The firm has a market cap of $41.61 million, a PE ratio of -0.29 and a beta of 1.95. The firm has a fifty day moving average price of $0.61 and a 200 day moving average price of $2.21. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.38 and a current ratio of 6.49. Outset Medical, Inc. has a fifty-two week low of $0.44 and a fifty-two week high of $6.37.

Analysts Set New Price Targets

OM has been the subject of a number of research reports. Royal Bank of Canada lowered shares of Outset Medical from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $6.00 to $3.00 in a research report on Thursday, August 8th. TD Cowen dropped their price objective on shares of Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.70.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.